Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules

被引:216
作者
Sung, BJ
Hwang, KY
Jeon, YH
Lee, JI
Heo, YS
Kim, JH
Moon, J
Yoon, JM
Hyun, YL
Kim, E
Eum, SJ
Park, SY
Lee, JO
Lee, TG
Ro, S
Cho, JM
机构
[1] CrystalGenom Inc, Div Drug Discovery, Taejon 305390, South Korea
[2] Yokohama City Univ, Prot Design Lab, Yokohama, Kanagawa 2300045, Japan
[3] Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea
关键词
D O I
10.1038/nature01914
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Phosphodiesterases (PDEs) are a superfamily of enzymes that degrade the intracellular second messengers cyclic AMP and cyclic GMP(1-3). As essential regulators of cyclic nucleotide signalling with diverse physiological functions, PDEs are drug targets for the treatment of various diseases, including heart failure, depression, asthma, inflammation and erectile dysfunction(4-7). Of the 12 PDE gene families, cGMP-specific PDE5 carries out the principal cGMP-hydrolysing activity in human corpus cavernosum tissue. It is well known as the target of sildenafil citrate (Viagra) and other similar drugs for the treatment of erectile dysfunction. Despite the pressing need to develop selective PDE inhibitors as therapeutic drugs, only the cAMP-specific PDE4 structures are currently available(8,9). Here we present the three-dimensional structures of the catalytic domain (residues 537-860) of human PDE5 complexed with the three drug molecules sildenafil, tadalafil (Cialis) and vardenafil (Levitra). These structures will provide opportunities to design potent and selective PDE inhibitors with improved pharmacological profiles.
引用
收藏
页码:98 / 102
页数:5
相关论文
共 23 条
[1]   CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES - FUNCTIONAL IMPLICATIONS OF MULTIPLE ISOFORMS [J].
BEAVO, JA .
PHYSIOLOGICAL REVIEWS, 1995, 75 (04) :725-748
[2]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[3]   RECENT PROGRESS IN UNDERSTANDING THE HORMONAL-REGULATION OF PHOSPHODIESTERASES [J].
CONTI, M ;
NEMOZ, G ;
SETTE, C ;
VICINI, E .
ENDOCRINE REVIEWS, 1995, 16 (03) :370-389
[4]   Cyclic GMP phosphodiesterase-5: Target of sildenafil [J].
Corbin, JD ;
Francis, SH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (20) :13729-13732
[5]  
Corbin JD, 2002, INT J CLIN PRACT, V56, P453
[6]   Preparation of selenomethionyl proteins for phase determination [J].
Doublie, S .
MACROMOLECULAR CRYSTALLOGRAPHY, PT A, 1997, 276 :523-530
[7]   MECHANISM OF CDK ACTIVATION REVEALED BY THE STRUCTURE OF A CYCLINA-CDK2 COMPLEX [J].
JEFFREY, PD ;
RUSO, AA ;
POLYAK, K ;
GIBBS, E ;
HURWITZ, J ;
MASSAGUE, J ;
PAVLETICH, NP .
NATURE, 1995, 376 (6538) :313-320
[8]   IMPROVED METHODS FOR BUILDING PROTEIN MODELS IN ELECTRON-DENSITY MAPS AND THE LOCATION OF ERRORS IN THESE MODELS [J].
JONES, TA ;
ZOU, JY ;
COWAN, SW ;
KJELDGAARD, M .
ACTA CRYSTALLOGRAPHICA SECTION A, 1991, 47 :110-119
[9]   Preparation of aromatic polycarbonate nanoparticles using supercritical carbon dioxide [J].
Lee, JY ;
Song, CH ;
Kim, JI ;
Kim, JH .
JOURNAL OF NANOPARTICLE RESEARCH, 2002, 4 (1-2) :53-59
[10]   Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling [J].
Mehats, C ;
Andersen, CB ;
Filopanti, M ;
Jin, SLC ;
Conti, M .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2002, 13 (01) :29-35